이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Endo International 대차 대조표 상태

재무 상태 기준 확인 2/6

Endo International 의 총 주주 지분은 $-6.6B 이고 총 부채는 $8.1B, 이는 부채 대 자기자본 비율을 -123.5% 로 가져옵니다. 총자산과 총부채는 각각 $5.1B 및 $11.7B 입니다.

주요 정보

-123.5%

부채 비율

US$8.15b

부채

이자 보상 비율	n/a
현금	US$777.92m
주식	-US$6.60b
총 부채	US$11.73b
총 자산	US$5.14b

최근 재무 상태 업데이트

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

재무 상태 분석

단기부채: ENDP.Q 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: ENDP.Q 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: ENDP.Q 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: ENDP.Q 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 수익성이 없는 ENDP.Q 현재의 플러스 무료 현금 흐름 수준을 유지한다면 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: ENDP.Q 은(는) 수익성이 없지만 잉여 현금 흐름이 양수이고 0.8 % 감소하더라도 3년 이상 충분한 현금 활주로를 보유하고 있습니다. 년도.

Endo International 대차 대조표 상태

재무 상태 기준 확인 2/6

주요 정보

최근 재무 상태 업데이트

Fourth Amended Reorganization Plan Filed by Endo International plc

Two Affiliate Companies Joined Endo International plc Bankruptcy

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Recent updates

Endo International plc to Report Q1, 2024 Results on May 30, 2024

Fourth Amended Reorganization Plan Filed by Endo International plc

Endo International plc to Report Q3, 2023 Results on Nov 06, 2023

Endo International plc, Annual General Meeting, Sep 07, 2023

Endo International plc Launches First Generic Version of Noxafil® (posaconazole) Injection

Endo International plc Announces First Patient Enrolled in Registry of Dupuytren's Contracture

Endo International plc Launches PREVDUO (Neostigmine Mylsulfate and Glycopyrrolate Injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Two Affiliate Companies Joined Endo International plc Bankruptcy

Endo International plc Announces Asset Impairment Charges for Three Months Ended March 31, 2023

Endo International plc and SMSNA Launches App to Provide Peyronie's Disease Self-Assessment Tool

Nasdaq to Delist Common Stock of Endo International

Endo International Provides Delisting Update

Endo International plc(NasdaqGS:ENDP) dropped from NASDAQ Biotechnology Index

Endo International plc(NasdaqGS:ENDP) dropped from S&P TMI Index

Endo International plc Filed for Bankruptcy

Endo International plc Filed for Bankruptcy

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Second quarter 2022 earnings released: US$8.00 loss per share (vs US$0.044 loss in 2Q 2021)

Endo International sees 23% rise on 3x higher than normal volume

Endo outperforms defying bankruptcy fears and generic entry

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International Receives Non-Compliance Notice from Nasdaq

Endo International cools off, giving back some of its 85% Tuesday gain

Endo International plc(NasdaqGS:ENDP) dropped from S&P Pharmaceuticals Select Industry Index

Endo: Stick A Fork In It

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

Price target decreased to US$2.63

Endo International plc to Report Q1, 2022 Results on May 05, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to its Board of Directors

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-To-Use Vials

Endo: About As Bad As It Gets

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Endo International plc Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

Price target decreased to US$6.17

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Investor sentiment deteriorated over the past week

Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.30 loss in 3Q 2020)

Investor sentiment improved over the past week

Endo: A Win In California But Equity Value Still A Question

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to US$6.57

Endo International: Loses Vasostrict Trial

Investor sentiment deteriorated over the past week

Endo International: Hires Restructuring Advisor

Consensus forecasts updated

Endo International: All About Ongoing Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.077 profit in 2Q 2020)

Investor sentiment improved over the past week

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Investor sentiment deteriorated over the past week

Endo International: Bankruptcy Seems Like The Only Practical Option

Endo International plc(NasdaqGS:ENDP) dropped from Russell 2500 Growth Index

Endo International wins FDA approval for Micafungin new formulation

Chairman Paul Campanelli has left the company

Senior Independent Director Roger Kimmel has left the company

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.69 in 1Q 2020)

Endo International plc Announces Asset Impairment Results for the First Quarter Ended March 31, 2021

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

Chairman exercised options and sold US$1.4m worth of stock

Investor sentiment deteriorated over the past week

Independent Director recently sold US$150k worth of stock

Investor sentiment deteriorated over the past week

Price target raised to US$7.45